GlassScriptPhysician profile
Jehanzeb Riaz
NPI 1205130218
$9,448.53
in general payments reported to CMS, 2019-2025
74 companies · $3,324 in 2025
The $3,324 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $250 · 2021: $257 · 2022: $242 · 2023: $601 · 2024: $3,680 · 2025: $3,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,250 · Education: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,249.58 |
| Education | $355.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,126.75 | 2019-2025 | |
| Pfizer INC. | $945.89 | 2019-2025 | |
| Abbvie INC. | $841.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $527.43 | 2019-2025 | Enhertu, Lynparza |
| Genentech USA, INC. | $425.95 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Merck Sharp & Dohme LLC | $315.18 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $306.00 | 2019-2025 | Rybrevant, Carvykti, Tecvayli |
| Daiichi Sankyo INC. | $280.26 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Genzyme Corporation | $266.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $260.21 | 2021-2023 | Xarelto |
| Pharmacosmos Therapeutics INC. | $243.19 | 2023-2025 | Monoferric |
| Astellas Pharma US INC | $232.28 | 2019-2025 | Xtandi, Xospata, Padcev |
| E.R. Squibb & Sons, L.L.C. | $209.19 | 2019-2025 | Opdivo |
| Celgene Corporation | $204.36 | 2024-2025 | Reblozyl, Breyanzi |
| Adaptive Biotechnologies Corporation | $193.01 | 2025 | Clonoseq |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $180.70 | 2019-2025 | Ninlaro, Vonvendi, Advate |
| Seagen INC. | $166.46 | 2019-2023 | Adcetris, Tukysa |
| Glaxosmithkline, LLC. | $164.62 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $144.72 | 2019-2025 | Jakafi, Monjuvi |
| Deciphera Pharmaceuticals INC. | $132.67 | 2023-2025 | Qinlock, Romvimza |
| Array Biopharma INC | $127.71 | 2023-2025 | Mektovi, Braftovi, Xalkori |
| Emd Serono, INC. | $109.53 | 2019-2025 | Bavencio |
| Regeneron Healthcare Solutions, INC. | $109.52 | 2019-2025 | Libtayo |
| Dendreon Pharmaceuticals LLC | $104.29 | 2024 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $88.70 | 2023-2025 | |
| Gilead Sciences, INC. | $81.46 | 2019-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $80.06 | 2019-2024 | Rezlidhia, Tavalisse |
| Amgen INC. | $78.88 | 2019-2020 | |
| Novo Nordisk INC | $73.75 | 2024-2025 | Esperoct |
| Sumitomo Pharma America, INC. | $71.65 | 2024-2025 | Orgovyx |
| Springworks Therapeutics, INC. | $70.14 | 2024-2025 | Ogsiveo |
| Lilly USA, LLC | $69.49 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Fresenius Kabi USA, LLC | $67.37 | 2024-2025 | Stimufend |
| Eisai INC. | $65.56 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $65.22 | 2024-2025 | Ultomiris |
| Iovance Biotherapeutics, INC. | $63.50 | 2025 | Amtagvi |
| Puma Biotechnology, INC. | $55.89 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $54.11 | 2025 | |
| Apellis Pharmaceuticals, INC. | $46.41 | 2024 | Empaveli |
| Jazz Pharmaceuticals INC. | $46.27 | 2019 | |
| Blueprint Medicines Corporation | $43.20 | 2020-2025 | Ayvakit |
| Octapharma USA, INC. | $39.14 | 2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Accord Healthcare, INC. | $38.71 | 2024-2025 | |
| Caris Mpi, INC. | $38.14 | 2025 | Mi Cancer Seek |
| Agios Pharmaceuticals, INC. | $36.02 | 2024 | Pyrukynd |
| Genmab U.S., INC. | $31.69 | 2024 | Tivdak |
| Spectrum Pharmaceuticals INC. | $30.20 | 2023-2024 | Rolvedon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.04 | 2019 | |
| Recordati_rare_diseases_inc. | $27.30 | 2025 | Enjaymo |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Legend Biotech USA INC. | $25.01 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $24.47 | 2024 | Xpovio |
| Tempus Ai, INC | $22.92 | 2025 | Xt Cdx |
| Immunogen, INC. | $22.43 | 2024 | Elahere |
| Mirati Therapeutics, INC. | $21.88 | 2024 | Krazati |
| Biocon Biologics INC | $21.71 | 2024 | Ogivri |
| Sun Pharmaceutical Industries INC. | $20.55 | 2024 | |
| Progenics Pharmaceuticals, INC. | $19.89 | 2025 | |
| Sobi, INC | $18.12 | 2025 | |
| Secura Bio, INC. | $18.11 | 2024 | Copiktra |
| Pharmacyclics LLC, An Abbvie Company | $17.89 | 2023 | Imbruvica |
| Teva Pharmaceuticals USA, INC. | $17.35 | 2019 | |
| Dova Pharmaceuticals | $17.30 | 2020 | |
| Invivyd INC | $16.55 | 2025 | Pemgarda |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Tazverik, Onivyde |
| Servier Pharmaceuticals LLC | $16.13 | 2025 | |
| Myriad Genetic Laboratories, INC. | $14.99 | 2024 | Myrisk |
| Alnylam Pharmaceuticals INC. | $14.28 | 2024 | Onpattro |
| Beone Medicines USA, INC. | $14.17 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $14.04 | 2023 | |
| Tersera Therapeutics LLC | $13.46 | 2025 | Quzyttir |
| Beigene USA, INC. | $13.35 | 2024 | Brukinsa |
| Verastem, INC. | $13.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jehanzeb Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.